- Home
- IONS vs UGI Comparison
IONS vs UGI Comparison
Compare IONS & UGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- UGI
- Stock Information
- Founded
- IONS 1989
- UGI 1940
- Country
- IONS United States
- UGI United States
- Employees
- IONS N/A
- UGI N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- UGI Natural Gas Distribution
- Sector
- IONS Health Care
- UGI Utilities
- Exchange
- IONS Nasdaq
- UGI Nasdaq
- Market Cap
- IONS 6.8B
- UGI 7.5B
- IPO Year
- IONS 1991
- UGI N/A
- Fundamental
- Price
- IONS $61.23
- UGI $34.58
- Analyst Decision
- IONS Buy
- UGI Buy
- Analyst Count
- IONS 17
- UGI 3
- Target Price
- IONS $67.88
- UGI $31.33
- AVG Volume (30 Days)
- IONS 3.1M
- UGI 1.8M
- Earning Date
- IONS 07-30-2025
- UGI 08-06-2025
- Dividend Yield
- IONS N/A
- UGI 4.34%
- EPS Growth
- IONS N/A
- UGI N/A
- EPS
- IONS N/A
- UGI 1.92
- Revenue
- IONS $944,050,000.00
- UGI $7,332,000,000.00
- Revenue This Year
- IONS $24.30
- UGI $10.33
- Revenue Next Year
- IONS $7.39
- UGI $16.58
- P/E Ratio
- IONS N/A
- UGI $18.05
- Revenue Growth
- IONS 16.05
- UGI N/A
- 52 Week Low
- IONS $23.95
- UGI $23.14
- 52 Week High
- IONS $62.08
- UGI $37.43
- Technical
- Relative Strength Index (RSI)
- IONS 83.44
- UGI 44.25
- Support Level
- IONS $42.13
- UGI $33.81
- Resistance Level
- IONS $62.08
- UGI $35.49
- Average True Range (ATR)
- IONS 2.11
- UGI 0.50
- MACD
- IONS 2.09
- UGI -0.04
- Stochastic Oscillator
- IONS 95.83
- UGI 45.83
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.